Effects of a selective phosphodiesterase IV inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthma

Canadian Journal of Physiology and Pharmacology

Volumn 76, Issue 2, 1998, Pages 210-217

  Jones, T R ^a   McAuliffe, M ^a   McFarlane, C S ^a   Piechuta, H ^a   Macdonald, D ^a   Rodger, I W ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Antigen induced bronchoconstriction; CDP 840; Non human primate; Selective phosphodiesterase IV inhibitor

Indexed keywords

1 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 1 PHENYL 2 (4 PYRIDYL)ETHANE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 4 BROMO 2,7 DIMETHOXY 3H PHENOTHIAZIN 3 ONE; 4 [2 (3 CYCLOPENTYLOXY 4 METHOXYPHENYL) 2 PHENYLETHYL]PYRIDINE; ASCARIS ANTIGEN; LEUKOTRIENE D4; MONTELUKAST; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG; VERLUKAST;

AIRWAY RESISTANCE; ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHOSPASM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SQUIRREL MONKEY;

EID: 0031779841     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y98-030     Document Type: Article

References (31)

1. Barnes, P.J. 1989. New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. J. Allergy Clin. Immunol. 83: 1013-1026.
2. Brideau, C., Chan, C., Charleson, S., Denis, D., Evans, J.F., Ford-Hutchinson, A.W., Fortin, R., Gillard, J.W., Guay, J., Guévremont, D., Hutchinson, J.H., Jones, T.R., Leger, S., Mancini, J.A., McFarlane, C.S., Pickett, C., Piechuta, H., Prasit, P., Riendeau, D., Rouzer, C.A., Tagari, P., Vickers, P.J., and Young, R.N. 1991. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-yl]-2, 2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol. 70: 799-807.
3. Creticos, P.S., Peters, S.P., Adkinson, N.F., Naclerio, R.M., Hayes, E.C., Norman, P.S., and Lichtenstein, L.M. 1984. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N. Engl. J. Med. 310: 1626-1630.
4. Eady, R.P., Greenwood, B., Jackson, D.M., Orr, T.S.C., and Wells, E. 1985. The effect of nedocromil sodium and sodium cromoglycate on antigen-induced bronchoconstriction in the ascaris-sensitive monkey. Br. J. Pharmacol. 85: 323-325.
5. Giembycz, M.A., and Dent, G. 1992. Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma. Clin. Exp. Allergy, 229: 331-334.
6. Gillard, J., Ford-Hutchinson, A.W., Chan, C., Charleson, S., Denis, D., Foster, A., Fortin, R., Leger, S., McFarlane, C.S., Morton, H., Piechuta, H., Riendeau, D., Rouzer, A., Rokach, J., and Young, R. 1989. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-(-butyl-thio-5-isopropylindol-2-yl]-2,2- dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol. 67: 456-464.
7. Gozzard, N., El Hashem, A., Herd, C.M., Blake, S.M., Holbrook, M., Hughes, B., Higgs, G.A., and Page, C.P. 1996. Effect of the steroid budesonide and a novel phosphodiesterase type IV inhibitor CDP-840 on antigen-induced pulmonary responses in neonatally immunized rabbits. Br. J. Pharmacol. 118: 1201-1208.
8. Heaslip, R.J., Hardysh, B.A., Berkenkopf, J.W., and Weichman, B.M. 1992. Effects of selective phosphodiesterase inhibitors on antigen-induced leukotriene release and leukotriene-dependent tracheal contraction. Am. Rev. Respir. Dis. 145: A859.
9. Hichami, A., Boichot, E., Germain, N., Legrand, A., Moodley, I., and Lagente, V. 1995. Involvement of cyclic AMP in the effects of phosphodiesterase IV inhibitors on arachidonate release from mononuclear cells. Eur. J. Pharmacol. 291: 91-97.
10. Holbrook, M., Gozzard, N., James, T., Higgs, G., and Hughes, B. 1996. Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea pig by CDP-840, a novel phosphodiesterase type 4 inhibitor. Br. J. Pharmacol. 118: 1192-1200.
11. Hughes, B., Holbrook, M., Allen, R., Owens, R., Perry, M., Warrellow, G., Howat, D., Bloxham, D., and Higgs, G. 1995. Suppression of antigen-induced airway responses and bronchial hyperresponsiveness by CDP-840, a novel, stereo-selective inhibitor of phosphodiesterase type IV. Br. J. Pharmacol. 116: 6P.
12. Hughes, B., Howat, D., Lisle, H., Holbrook, M., James, T., Gozzard, N., Blease, K., Hughes, P., Kingaby, R., Warrellow, G., Alexander, R., Head, J., Boyd, E., Eaton, M., Perry, M., Wales, M., Smith, B., Owens, R., Catterall, C., Lumb, S., Russell, A., Allen, R., Merriman, M., Bloxham, D., and Higgs, G. 1996. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP-840, a novel stereo-selective inhibitor of phosphodiesterase type IV. Br J Pharmacol 118: 1183-1191.
13. Hutchinson, J.H., Riendeau, D., Brideau, C., Chan, C., Delorme, D., Denis, D., Falgueyret, J.-P., Fortin, R., Guay, J., Hamel, P., Jones, T.R., MacDonald, D., McFarlane, C.S., Piechuta, H., Scheigetz, J., Tagari, P., Therien, M., and Girard, Y. 1993. Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816. J. Med. Chem. 36: 2771-2787.
14. 4 receptor antagonist. Can. J. Physiol. Pharmacol. 67: 17-28.
15. Jones, T.R., Zamboni, R., Belley, M., Champion, E., Charette, L., Ford-Hutchinson, A.W., Gauthier, J.-Y., Leger, S., Lord, A., Masson, P., McFarlane, C.S., Metters, K.M., Pickett, C., Piechuta, H., and Young, R.N. 1991. Pharmacology of the leukotriene antagonist verlukast: the (R)-enantiomer of MK-571. Can. J. Physiol. Pharmacol. 69: 1847-1854.
16. 4 receptor antagonist. Can. J. Physiol. Pharmacol. 73: 191-201.
17. 4 levels during early and late asthmatic responses. J. Allergy Clin. Immunol. 86: 211-220.
18. 4-receptor antagonist, in patients with chronic asthma. J. Allergy Clin. Immunol. 87: 309.
19. McFarlane, C.S., Hamel, R., and Ford-Hutchinson, A.W. 1987. Effects of a 5-lipoxygenase inhibitor (L-651,392) on primary and late pulmonary responses to ascaris antigen in the squirrel monkey. Agents Actions, 22: 63-68.
20. 4) receptor antagonist, on ascaris antigen-induced early and late phase airway responses in conscious squirrel monkeys. Am. J. Respir. Crit. Care Med. 149: A533.
21. O'Neil, R.M., and Goodman, F.R. 1981. Respiratory responses to ascaris antigen in rhesus and cynomolgus monkeys. J. Allergy Clin. Immunol. 67: 229-236.
22. Patterson, R., and Harris, K.E. 1978. Aerosolized antigen dose-response studies in asthmatic monkeys. J. Lab. Clin. Med. 92: 283-287.
23. 4 and ascaris antigen-induced airway responses in rhesus monkeys. Int. Arch. Allergy Appl. Immunol. 86: 440-445.
24. Qian, Y., Girard, V., Martin, C.A.E., Molinard, M., and Advenier, C. 1994. Rolipram but not siguazodan or zaprinast, inhibits the excitatory noncholinergic neurotransmission in guinea pig bronchi. Eur. Respir. J. 7:306-310.
25. 4-receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J. Allergy Clin. Immunol. 90: 193-201.
26. 4 receptor antagonist, in subjects with bronchial asthma. Am. J. Respir. Crit. Care Med. 150: 618-623.
27. 4 excretion in allergic asthmatics after inhaled antigen. Eicosanoids, 3: 75-80.
28. Torphy, T.J., and Undem, B.J. 1991. Phosphodiesterase inhibitors. New opportunities for the treatment of asthma. Thorax, 46: S12-S23.
29. Turner, C.R., Andresen, C.J., Smith, W.B., and Watson, J.W. 1994. Effects of rolipram on responses to acute and chronic antigen exposure in monkeys. Am. J. Respir. Crit. Care Med. 149: 1153-1159.
30. Underwood, D.C., Osborn, R.R., Osbourne, R.L., Novak, L.B., Mathews, J.K., Newsholme, S.J., Undem, B.J., Hand, J.M., and Torphy, T.J. 1993. Inhibition of antigen-induced bronchconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP specific phosphodiesterase inhibitor, rolipram. J. Pharmacol. Exp. Ther. 266: 306-313.
31. Underwood, D.C., Kotzer, C.J., Bochnowicz, K.S., Osborn, R.R., Luttman, M.A., Hay, D.W.P., and Torphy, T.J. 1994. Comparison of phosphodiesterase II, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pig. J. Pharmacol. Exp. Ther. 270: 250-259.